Stay updated on Fulvestrant + Neratinib in Breast Cancer (HER2-Signal) Clinical Trial
Sign up to get notified when there's something new on the Fulvestrant + Neratinib in Breast Cancer (HER2-Signal) Clinical Trial page.

Latest updates to the Fulvestrant + Neratinib in Breast Cancer (HER2-Signal) Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe record history now lists revision v3.3.2 and removes v3.2.0.SummaryDifference0.1%

- Check20 days agoChange DetectedRemoved the general government funding and operating status notice from the page, and the trial record content remains unchanged; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.8%

- Check35 days agoChange DetectedStudy Status was updated in version 2 on 2021-10-25. Recruitment Status was updated in version 3 on 2023-07-26.SummaryDifference0.1%

- Check64 days agoChange Detected- Added a government funding lapse notice and current operating status guidance for NIH Clinical Center, and a version bump to v3.2.0. - Removed the previous version tag v3.1.0.SummaryDifference13%

- Check71 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.3%

- Check85 days agoChange DetectedUpdated revision from v3.0.1 to v3.0.2 and removed the Back to Top element; no substantive changes to core content, pricing, stock, or time-related information.SummaryDifference0.8%

Stay in the know with updates to Fulvestrant + Neratinib in Breast Cancer (HER2-Signal) Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fulvestrant + Neratinib in Breast Cancer (HER2-Signal) Clinical Trial page.